OBJECTIVE: To assess the frequency with which patients with epithelial ovarian cancer are enrolled in prospective Gynecologic Oncology Group (GOG) treatment studies and to assess whether enrollment is influenced by patient age or other factors. METHODS: The study was open to patients with primary, previously untreated epithelial ovarian cancer referred to member institutions. Eligible patients provided written informed consent to have demographic and medical records data submitted to the protocol database for analysis. Pathologic diagnosis was confirmed by central review. Demographic and clinical data, including coexisting medical conditions, tumor stage, grade, and histology, surgical procedures, planned postoperative therapy, and reason/s (if applicable) a patient was not treated per GOG protocol, were collected. RESULTS: Nine hundred and forty-eight patients were initially eligible. Subsequently, 137 (15%) patients were excluded based on pathology (low malignant potential tumors), as were 10 whose invasive disease was unstaged. Among 801 eligible patients, 36% were > or =65 years of age, 52% had papillary serous tumors, and 73% had stage III/IV disease. In patients aged <65 years, 67% were stage III/IV compared to 82% of patients > or =65 years of age. The mean age was 5.5 years greater for patients with stage III/IV versus stage I/II disease. Compared to their younger counterparts, older patients with stage III/IV disease were less likely to enter into a GOG treatment protocol. Most common reasons were patient ineligibility (33%), refusal (29%), and investigator decision (20%). CONCLUSION: Age appears to be an important factor influencing treatment selection among patients with stage III/IV ovarian cancer. In addition to reviewing eligibility criteria, practitioners' attitudes should be monitored to assure that elderly patients are not inappropriately denied participation in GOG clinical trials.
OBJECTIVE: To assess the frequency with which patients with epithelial ovarian cancer are enrolled in prospective Gynecologic Oncology Group (GOG) treatment studies and to assess whether enrollment is influenced by patient age or other factors. METHODS: The study was open to patients with primary, previously untreated epithelial ovarian cancer referred to member institutions. Eligible patients provided written informed consent to have demographic and medical records data submitted to the protocol database for analysis. Pathologic diagnosis was confirmed by central review. Demographic and clinical data, including coexisting medical conditions, tumor stage, grade, and histology, surgical procedures, planned postoperative therapy, and reason/s (if applicable) a patient was not treated per GOG protocol, were collected. RESULTS: Nine hundred and forty-eight patients were initially eligible. Subsequently, 137 (15%) patients were excluded based on pathology (low malignant potential tumors), as were 10 whose invasive disease was unstaged. Among 801 eligible patients, 36% were > or =65 years of age, 52% had papillary serous tumors, and 73% had stage III/IV disease. In patients aged <65 years, 67% were stage III/IV compared to 82% of patients > or =65 years of age. The mean age was 5.5 years greater for patients with stage III/IV versus stage I/II disease. Compared to their younger counterparts, older patients with stage III/IV disease were less likely to enter into a GOG treatment protocol. Most common reasons were patient ineligibility (33%), refusal (29%), and investigator decision (20%). CONCLUSION: Age appears to be an important factor influencing treatment selection among patients with stage III/IV ovarian cancer. In addition to reviewing eligibility criteria, practitioners' attitudes should be monitored to assure that elderly patients are not inappropriately denied participation in GOG clinical trials.
Authors: Charles L Wiggins; Linda C Harlan; Harold E Nelson; Jennifer L Stevens; Cheryl L Willman; Edward N Libby; Robert A Hromas Journal: Am J Med Date: 2010-08 Impact factor: 4.965
Authors: Terrance L Albrecht; Susan S Eggly; Marci E J Gleason; Felicity W K Harper; Tanina S Foster; Amy M Peterson; Heather Orom; Louis A Penner; John C Ruckdeschel Journal: J Clin Oncol Date: 2008-06-01 Impact factor: 44.544
Authors: Veronica Di Carlo; Jacques Estève; Christopher Johnson; Fabio Girardi; Hannah K Weir; Reda J Wilson; Pamela Minicozzi; Rosemary D Cress; Charles F Lynch; Karen S Pawlish; Judith R Rees; Michel P Coleman; Claudia Allemani Journal: JNCI Cancer Spectr Date: 2020-09-14
Authors: Mina S Sedrak; Supriya G Mohile; Virginia Sun; Can-Lan Sun; Bihong T Chen; Daneng Li; Andrew R Wong; Kevin George; Simran Padam; Jennifer Liu; Vani Katheria; William Dale Journal: J Geriatr Oncol Date: 2019-07-31 Impact factor: 3.599
Authors: Mina S Sedrak; Rachel A Freedman; Harvey J Cohen; Hyman B Muss; Aminah Jatoi; Heidi D Klepin; Tanya M Wildes; Jennifer G Le-Rademacher; Gretchen G Kimmick; William P Tew; Kevin George; Simran Padam; Jennifer Liu; Andrew R Wong; Andrea Lynch; Benjamin Djulbegovic; Supriya G Mohile; William Dale Journal: CA Cancer J Clin Date: 2020-10-01 Impact factor: 508.702
Authors: Joseph M Unger; Dawn L Hershman; Cathee Till; Lori M Minasian; Raymond U Osarogiagbon; Mark E Fleury; Riha Vaidya Journal: J Natl Cancer Inst Date: 2021-03-01 Impact factor: 13.506